Prognostic impact of nodal involvement in Waldenström macroglobulinaemia.
Waldenström's macroglobulinaemia
extra‐medullary disease
histological transformation
non‐Hodgkin's lymphoma
prognosis
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
received:
03
08
2024
accepted:
22
09
2024
medline:
1
10
2024
pubmed:
1
10
2024
entrez:
1
10
2024
Statut:
aheadofprint
Résumé
The clinical and prognostic implications of nodal involvement (NI) in Waldenström macroglobulinaemia (WM) are largely unknown. In this study, we explored the impact of NI on clinical presentation and outcome in a population-based cohort of 469 patients with WM, consecutively diagnosed between 2000 and 2022. NI was detected in 34% of patients and was associated with symptomatic disease, adverse prognostic factors, an increased risk of transformation, and lymphoma-related death. Our findings indicate that NI is of prognostic significance in WM, suggesting a need for enhanced surveillance in these patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Region Sjælland
ID : R32-A1056
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Dogliotti I, Jiménez C, Varettoni M, Talaulikar D, Bagratuni T, Ferrante M, et al. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. Leukemia. 2023;37(2):388–395.
Cao X, Ye Q, Orlowski RZ, Wang X, Loghavi S, Tu M, et al. Waldenström macroglobulinemia with extramedullary involvement at initial diagnosis portends a poorer prognosis. J Hematol Oncol. 2015;8:74.
Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, et al. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015;90(2):100–104.
Brice P, Bastion Y, Lepage E, Brousse N, Haïoun C, Moreau P, et al. Comparison in low‐tumor‐burden follicular lymphomas between an initial no‐treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15(3):1110–1117.
Solal‐Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz‐Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–1265.
Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013;160(2):171–176.
García‐Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582.
Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022–2035.
Banwait R, O'Regan K, Campigotto F, Harris B, Yarar D, Bagshaw M, et al. The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011;86(7):567–572.
Pan B, Zhu X, Xie Q. The performance and applied value of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Nucl Med Mol Imaging. 2023;13(5):217–224.
Pophali PA, Bartley A, Kapoor P, Gonsalves WI, Ashrani AA, Marshall AL, et al. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014–1017.
Talaulikar D, Tomowiak C, Toussaint E, Morel P, Kapoor P, Castillo JJ, et al. Evaluation and management of disease transformation in Waldenström macroglobulinemia. Hematol Oncol Clin North Am. 2023;37(4):787–799.
Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S, et al. Impact of MYD88L265P mutation status on histological transformation of Waldenström macroglobulinemia. Am J Hematol. 2020;95(3):274–281.
Morel P, Duhamel A, Gobbi P, Dimopoulos MA, Dhodapkar MV, McCoy J, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170.
Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsonis MC, Durot E, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019;33(11):2654–2661.